Aurinia to Host Conference Call & Webcast to Review Results from the AURION Study Conference Call and Webcast with Slides, Tuesday February 16th at 4.30pm Eastern Time VICTORIA, British Columbia--(BUSINESS WIRE)

to Host Conference Call & Webcast to Review Results from the AURION Study

Call and Webcast with Slides, Tuesday February 16th at 4.30pm Eastern

VICTORIA, British Columbia--(BUSINESS WIRE)--February 11, 2016--Aurinia

Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the

"Company") will host a conference call and live webcast to discuss

detailed results from its open label, single arm exploratory AURION (Aurinia

early Urinary protein Reduction

Predicts Response) study on Tuesday, February 16 at 4:30pm Eastern

Standard Time. Participating in the call will be Stephen Zaruby, CEO,

Dr. Neil Solomons, Chief Medical Officer, and Michael Martin, Chief

Tuesday, February 16, 2016 @ 4:30pm Eastern/1:30pm Pacific

International: 719-785-1753

Conference ID: 3145908

with slides: http://public.viavid.com/index.php?id=118297

Replays, through March 1, 2016

Domestic: 877-870-5176

Conference ID: 3145908

Aurinia is a clinical stage pharmaceutical company focused on the global

nephrology market. The fully-enrolled 265 patient Phase 2b AURA-LV

clinical trial is evaluating the efficacy of its lead drug, voclosporin,

as a treatment for active LN. LN is an inflammation of the kidneys, that

if inadequately treated can lead to end-stage renal disease, making LN a

serious and potentially life-threatening condition.

Voclosporin is a novel and potentially best-in-class calcineurin

inhibitor ("CNI") with extensive clinical data in over 2,000 patients in

other indications. Voclosporin is made by a modification of a single

amino acid of the cyclosporine molecule (a CNI approved for use in

transplant patients since 1983). This modification results in a more

predictable pharmacokinetic and pharmacodynamic relationship, an

increase in potency vs. cyclosporine, an altered metabolic profile, and

potential for flat dosing.

The AURION study or "Aurinia Early Urinary Protein Reduction Predicts

Response Study" is an open label, exploratory study being conducted in

multiple sites in Malaysia to assess the short term predictors of

response using voclosporin (23.7mg) in combination with mycophenolate

mofetil and oral corticosteroids in patients with active lupus

nephritis. This study will examine biomarkers of disease activity at 8

weeks and their ability to predict response at 24 and 48 weeks.

We seek Safe Harbor.

For More Information:

Pharmaceuticals Inc.

Mr. Michael Martin, 250-708-4272

Financial Communications Inc.

Barry Mire, 416-644-2020